Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Clinical trial NCT04024228 · COMPLETED
Trial details
- NCT number
- NCT04024228
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-28
- Primary completion
- 2020-01-09
- Enrollment
- 1539
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.